secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001104659-24-043158
Event type: litigation
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance settles derivative suit over director compensation; $600k fee, option cancellations
--------------------------------------------------------------------------------

- Iovance cancels 12,796 (2019), 11,731 (2020), 8,603 (2021) options to non-employee directors; awards reduced below 75th peer percentile.
- Governance reforms cap director comp at 75th percentile through 2027, limit options to 60% of equity grants, require annual comp consultant review.
- Iovance pays $600,000 for plaintiff attorney fees (court approval required); no admission of wrongdoing by defendants.
- Settlement hearing scheduled for July 11, 2024; if approved, derivative action dismissed with prejudice.
- Stockholders may object by July 1, 2024 with proof of ownership and grounds; otherwise barred from contesting settlement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924043158/0001104659-24-043158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465924043158/tm2410795d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-043158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer